PRESS RELEASE published on 01/09/2025 at 15:30, 1 year 1 month ago Formycon included in TecDAX Index of Deutsche Börse Formycon AG to be included in TecDAX Index of Deutsche Börse, enhancing visibility and market position. Company specializes in biosimilars for various disease areas Formycon AG Biosimilars Deutsche Börse TecDAX Index Technology Stocks
BRIEF published on 01/08/2025 at 14:35, 1 year 1 month ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
BRIEF published on 01/08/2025 at 14:35, 1 year 1 month ago Santé Canada approuve le médicament biosimilaire FYB202/Otulfi® de Formycon Formycon Ustekinumab Coûts Des Soins De Santé Biosimilaire Approbation Du Canada
PRESS RELEASE published on 01/08/2025 at 14:30, 1 year 1 month ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 1 year 1 month ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
BRIEF published on 12/11/2024 at 16:31, 1 year 1 month ago Formycon AG maintient de solides perspectives de croissance dans un contexte de marché difficile Formycon AG Baisse Des Revenus Approbation De La FDA Biosimilaires Lancement De Stelara
PRESS RELEASE published on 12/11/2024 at 16:26, 1 year 1 month ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 1 year 2 months ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
BRIEF published on 12/09/2024 at 06:35, 1 year 2 months ago MS Pharma va commercialiser FYB202 dans la région MENA Formycon AG MS Pharma Région MENA FYB202 Biosimilaires
PRESS RELEASE published on 12/09/2024 at 06:30, 1 year 2 months ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
Published on 02/10/2026 at 13:30, 35 minutes ago Revival Gold Intercepts 1.0 g/t Gold Over 30 Meters and Extends Mineralization at Mercur Project in Utah
Published on 02/10/2026 at 13:30, 35 minutes ago Metallic Minerals Provides Keno Silver Project Update and Details 2026 Exploration Plans
Published on 02/10/2026 at 13:00, 1 hour 5 minutes ago Kalo Gold Advances 2026 Target Development at Vatu Aurum; Lidar and Orthophotography Completed; Airborne Geophysics Planned for February
Published on 02/10/2026 at 13:00, 1 hour 5 minutes ago NOA Lithium Announces Additional Warrant Exercises for $818,000
Published on 02/10/2026 at 13:00, 1 hour 5 minutes ago Neural Cloud Retains Commission Wolf to Accelerate U.S. Commercial Expansion
Published on 02/10/2026 at 13:39, 26 minutes ago EQS-Adhoc: Salzgitter Aktiengesellschaft: Preliminary financials for the financial year 2025; Management Guidance 2026 approved
Published on 02/10/2026 at 13:39, 26 minutes ago Bernd Spalt fulfils current contract – but does not seek extension
Published on 02/10/2026 at 13:35, 30 minutes ago Bernd Spalt fulfils current contract – but does not seek extension
Published on 02/10/2026 at 13:15, 50 minutes ago SCOPE’s Ultra-Luxury Residential Performance Underscores Strong Investor Confidence in Thailand’s Prime Market
Published on 02/10/2026 at 13:08, 57 minutes ago Commerzbank exceeds profit target and launches further share buyback of up to €540m – dividend for 2025 to be €1.10 per share
Published on 02/09/2026 at 18:00, 20 hours 5 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 janvier 2026
Published on 02/09/2026 at 17:45, 20 hours 20 minutes ago Declaration of voting rights at the end of January 2026
Published on 02/09/2026 at 17:45, 20 hours 20 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 janvier 2026
Published on 02/09/2026 at 17:45, 20 hours 20 minutes ago Déclaration des droits de vote à fin janvier 2026
Published on 02/09/2026 at 17:45, 20 hours 20 minutes ago Déclaration des droits de vote à fin janvier 2026
